Boyd Watterson Asset Management Has Decreased Its Medtronic Plc (MDT) Holding by $326,400 as Share Value Rose; As Abbvie (ABBV) Stock Value Declined, Shareholder Comerica Securities Decreased Its Holding

June 14, 2018 - By Peter Erickson

Medtronic plc (NYSE:MDT) Logo

Comerica Securities Inc decreased its stake in Abbvie Inc (ABBV) by 15.96% based on its latest 2018Q1 regulatory filing with the SEC. Comerica Securities Inc sold 9,679 shares as the company’s stock declined 16.83% with the market. The institutional investor held 50,983 shares of the major pharmaceuticals company at the end of 2018Q1, valued at $4.83 million, down from 60,662 at the end of the previous reported quarter. Comerica Securities Inc who had been investing in Abbvie Inc for a number of months, seems to be less bullish one the $149.63B market cap company. The stock increased 1.28% or $1.245 during the last trading session, reaching $98.825. About 2.70M shares traded. AbbVie Inc. (NYSE:ABBV) has risen 52.41% since June 14, 2017 and is uptrending. It has outperformed by 39.84% the S&P500. Some Historical ABBV News: 08/05/2018 – OncoSec Expands Relationship with Merck, Announces Clinical Collaboration to Evaluate Combination of lmmunoPulse® IL-12 and KEYTRUDA® (pembrolizumab) for Triple Negative Breast Cancer; 13/03/2018 – AbbVie Announces Positive Topline Results from Second Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine F; 02/05/2018 – Positive Federal Legislation Could Lead to Exponential Growth in Marijuana and CBD Industry; 09/04/2018 – ABBVIE: UPADACITINIB MEETS ALL PRIMARY, SECONDARY ENDPOINTS; 17/04/2018 – LUPIN GETS TENTATIVE FDA APPROVAL FOR GENERIC ANDROGEL; 17/04/2018 – REG-Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2018; 06/04/2018 – INCYTE CORP – EDMC REVIEW OF PHASE 3 ECHO-301/KEYNOTE-252 STUDY EVALUATING EPACADOSTAT WITH KEYTRUDA DETERMINED STUDY DID NOT MEET PRIMARY ENDPOINT; 09/04/2018 – ABBVIE INC – PLANS GLOBAL REGULATORY SUBMISSIONS FOR UPADACITINIB IN RHEUMATOID ARTHRITIS IN SECOND HALF OF 2018; 22/03/2018 – ABBVIE REPORTS RESULTS FROM PHASE 2 STUDY EVALUATING ROVALPITUZ; 15/04/2018 – Merck: Safety Profile of Keytruda Consistent With Previous Trials of Patients With Advanced Melanoma

Boyd Watterson Asset Management Llc decreased its stake in Medtronic Plc (MDT) by 21.26% based on its latest 2018Q1 regulatory filing with the SEC. Boyd Watterson Asset Management Llc sold 4,080 shares as the company’s stock rose 4.71% while stock markets declined. The institutional investor held 15,107 shares of the electromedical & electrotherapeutic apparatus company at the end of 2018Q1, valued at $1.21 million, down from 19,187 at the end of the previous reported quarter. Boyd Watterson Asset Management Llc who had been investing in Medtronic Plc for a number of months, seems to be less bullish one the $117.24B market cap company. The stock increased 0.85% or $0.73 during the last trading session, reaching $86.57. About 2.49M shares traded. Medtronic plc (NYSE:MDT) has risen 0.84% since June 14, 2017 and is uptrending. It has underperformed by 11.73% the S&P500. Some Historical MDT News: 06/05/2018 – CHINA EVERBRIGHT TO BUY LIFTECH STAKE FROM MEDTRONIC; 16/05/2018 – Medtronic Begins U.S. Study of Drug-Eluting Stents to Evaluate Treatment of Bifurcation Lesions in Patients with Coronary Artery Disease; 30/04/2018 – Fidelity Dividend Income Adds Comcast, Cuts Medtronic; 08/03/2018 – Medtronic EVP & CVG President Mike Coyle to Speak at Cowen Healthcare Conference; 11/05/2018 – MEDTRONIC: FEASIBILITY OF EXTRAVASCULAR APPROACH TO ICD THERAPY; 07/05/2018 – Medtronic Hires JPMorgan Analyst, and Investors Rate It a `Buy’; 24/05/2018 – Medtronic Sees FY19 Adj EPS $5.10-Adj EPS $5.15; 10/04/2018 – MEDTRONIC EXPANDS VISUALASE(TM) MRI-GUIDED LASER ABLATION; 19/03/2018 – MEDTRONIC – ANNOUNCED 1-YR RESULTS FROM CRYO4PERSISTENT AF STUDY OF ABLATION WITH ARCTIC FRONT ADVANCE CRYOBALLOON; 09/04/2018 – MDT GETS FDA APPROVAL TO START IDE TRIAL FOR SYMPLICITY SPYRAL

More notable recent Medtronic plc (NYSE:MDT) news were published by: Seekingalpha.com which released: “Medtronic slips 1% after Analyst Day” on June 05, 2018, also Seekingalpha.com with their article: “Medtronic plc 2018 Q4 – Results – Earnings Call Slides” published on May 24, 2018, Investorplace.com published: “Is This the Latest Booster for Medtronic PLC Stock?” on June 14, 2018. More interesting news about Medtronic plc (NYSE:MDT) were released by: Globenewswire.com and their article: “Medtronic Launches New Clinician Programmer for Deep Brain Stimulation Therapy” published on June 13, 2018 as well as Globenewswire.com‘s news article titled: “Medtronic to Participate in Goldman Sachs Global Healthcare Conference” with publication date: May 29, 2018.

Among 30 analysts covering Medtronic (NYSE:MDT), 19 have Buy rating, 0 Sell and 11 Hold. Therefore 63% are positive. Medtronic had 89 analyst reports since August 10, 2015 according to SRatingsIntel. SunTrust maintained the shares of MDT in report on Monday, June 13 with “Buy” rating. The company was maintained on Thursday, February 22 by Citigroup. The company was maintained on Monday, October 9 by Needham. As per Friday, November 17, the company rating was maintained by SunTrust. The firm has “Outperform” rating by William Blair given on Thursday, July 6. The stock of Medtronic plc (NYSE:MDT) earned “Buy” rating by Jefferies on Tuesday, November 21. Needham maintained Medtronic plc (NYSE:MDT) on Friday, August 26 with “Buy” rating. The rating was maintained by Bank of America on Thursday, May 24 with “Buy”. The firm has “Market Perform” rating by Wells Fargo given on Monday, October 9. The stock of Medtronic plc (NYSE:MDT) earned “Hold” rating by Northland Capital on Wednesday, August 23.

Boyd Watterson Asset Management Llc, which manages about $4.87 billion and $201.45M US Long portfolio, upped its stake in Capital One Financial Corp (NYSE:COF) by 3,741 shares to 7,614 shares, valued at $730,000 in 2018Q1, according to the filing. It also increased its holding in Ishares Jp Morgan Emb (EMB) by 11,744 shares in the quarter, for a total of 27,809 shares, and has risen its stake in Bank Of America Corp (NYSE:BAC).

Analysts await Medtronic plc (NYSE:MDT) to report earnings on August, 28. They expect $1.13 EPS, up 0.89% or $0.01 from last year’s $1.12 per share. MDT’s profit will be $1.53B for 19.15 P/E if the $1.13 EPS becomes a reality. After $1.42 actual EPS reported by Medtronic plc for the previous quarter, Wall Street now forecasts -20.42% negative EPS growth.

Investors sentiment increased to 1.08 in Q1 2018. Its up 0.06, from 1.02 in 2017Q4. It increased, as 80 investors sold MDT shares while 383 reduced holdings. 88 funds opened positions while 414 raised stakes. 1.04 billion shares or 0.00% more from 1.04 billion shares in 2017Q4 were reported. Boyd Watterson Asset Management Ltd Liability Oh invested in 0.6% or 15,107 shares. Private Trust Com Na stated it has 0.2% of its portfolio in Medtronic plc (NYSE:MDT). Aureus Asset Mgmt Ltd Co stated it has 4,085 shares or 0.05% of all its holdings. Chemung Canal Tru holds 0.62% in Medtronic plc (NYSE:MDT) or 32,238 shares. Altrinsic Glob Advsrs Ltd Llc invested in 1.70M shares. Oakworth holds 0.05% or 2,787 shares. Baystate Wealth Limited Liability Co reported 571 shares stake. First Mercantile Com, a Tennessee-based fund reported 44,786 shares. Balyasny Asset Mgmt Ltd Liability accumulated 1.71 million shares. The California-based Clifford Swan Investment Counsel Lc has invested 0.08% in Medtronic plc (NYSE:MDT). Jarislowsky Fraser Limited holds 0.19% or 380,215 shares. 53,989 were accumulated by Liberty Mutual Gru Asset Mngmt. Burney Communication invested 0.05% of its portfolio in Medtronic plc (NYSE:MDT). Vestor Limited Liability Corporation reported 143,175 shares stake. Pennsylvania-based Somerset Trust Company has invested 2.28% in Medtronic plc (NYSE:MDT).

Investors sentiment decreased to 0.7 in Q1 2018. Its down 0.10, from 0.8 in 2017Q4. It dived, as 61 investors sold ABBV shares while 737 reduced holdings. 127 funds opened positions while 428 raised stakes. 1.06 billion shares or 0.67% less from 1.06 billion shares in 2017Q4 were reported. Yorktown Mgmt Research has 0.5% invested in AbbVie Inc. (NYSE:ABBV) for 17,800 shares. Fort Point Capital Prtnrs Ltd Com invested in 2.95% or 116,284 shares. Guyasuta Invest Incorporated reported 23,466 shares. Omers Administration Corp accumulated 51,900 shares or 0.05% of the stock. Ameriprise Financial Inc holds 0.21% or 4.90 million shares in its portfolio. Altfest L J And Inc invested 0.8% of its portfolio in AbbVie Inc. (NYSE:ABBV). Mariner Ltd Liability holds 49,113 shares or 0.17% of its portfolio. Thompson Siegel & Walmsley Ltd Liability stated it has 0.06% in AbbVie Inc. (NYSE:ABBV). Oppenheimer & Communications owns 200,543 shares. Paradigm Asset Mngmt Ltd Co stated it has 22,700 shares or 0% of all its holdings. Steinberg Glob Asset Mgmt invested 0.94% of its portfolio in AbbVie Inc. (NYSE:ABBV). 30,772 were reported by Glob X Management Com Limited Liability Company. Caprock Incorporated invested 0.33% in AbbVie Inc. (NYSE:ABBV). Gradient Limited Liability Corp holds 74,733 shares. Dreman Value Management L L C reported 21,065 shares stake.

Analysts await AbbVie Inc. (NYSE:ABBV) to report earnings on July, 27. They expect $1.97 earnings per share, up 38.73% or $0.55 from last year’s $1.42 per share. ABBV’s profit will be $2.98 billion for 12.54 P/E if the $1.97 EPS becomes a reality. After $1.87 actual earnings per share reported by AbbVie Inc. for the previous quarter, Wall Street now forecasts 5.35% EPS growth.

Since December 18, 2017, it had 0 buys, and 10 insider sales for $33.62 million activity. ALBAN CARLOS had sold 83,574 shares worth $9.57M. 2,643 shares were sold by SEVERINO MICHAEL, worth $311,684. 1,337 shares were sold by SALEKI-GERHARDT AZITA, worth $157,458. $976,084 worth of AbbVie Inc. (NYSE:ABBV) was sold by GONZALEZ RICHARD A. 18,129 shares valued at $2.15M were sold by RICHMOND TIMOTHY J. on Wednesday, February 28. Schumacher Laura J sold $2.95 million worth of AbbVie Inc. (NYSE:ABBV) on Wednesday, February 28.

Among 24 analysts covering Abbvie Inc (NYSE:ABBV), 9 have Buy rating, 3 Sell and 12 Hold. Therefore 38% are positive. Abbvie Inc had 96 analyst reports since July 21, 2015 according to SRatingsIntel. The stock has “Hold” rating by Leerink Swann on Thursday, March 22. The stock of AbbVie Inc. (NYSE:ABBV) earned “Equal-Weight” rating by Morgan Stanley on Monday, April 30. The firm earned “Buy” rating on Monday, June 26 by Jefferies. As per Friday, June 1, the company rating was downgraded by Piper Jaffray. The stock of AbbVie Inc. (NYSE:ABBV) has “Buy” rating given on Friday, February 2 by Argus Research. On Monday, November 2 the stock rating was upgraded by Morgan Stanley to “Overweight”. BMO Capital Markets maintained the shares of ABBV in report on Friday, March 23 with “Underperform” rating. The company was maintained on Wednesday, June 7 by Credit Suisse. The firm earned “Hold” rating on Tuesday, March 15 by Deutsche Bank. Jefferies maintained the shares of ABBV in report on Thursday, January 4 with “Buy” rating.

More notable recent AbbVie Inc. (NYSE:ABBV) news were published by: Fool.com which released: “Humira’s Sales Will Decline — and It’s Fantastic News for AbbVie” on June 13, 2018, also Seekingalpha.com with their article: “Premarket analyst action – healthcare” published on May 24, 2018, Seekingalpha.com published: “More Thoughts On AbbVie’s Rova-T Implosion” on June 06, 2018. More interesting news about AbbVie Inc. (NYSE:ABBV) were released by: Fool.com and their article: “3 Reasons to Expect Smooth Sailing for AbbVie’s Mission-Critical Candidate” published on June 10, 2018 as well as Fool.com‘s news article titled: “Is AbbVie Inc. (ABBV) a Buy?” with publication date: May 30, 2018.

AbbVie Inc. (NYSE:ABBV) Ratings Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>